![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SC Black, CS Schasteen, RH Weiss, DP Riley, EM Driscoll and BR Lucchesi
Department of Pharmacology, University of Michigan Medical School, Ann Arbor.
We determined whether an organic superoxide dismutase mimetic could reduce myocardial injury resulting from a 90-min occlusion of the left circumflex coronary artery, followed by 18 hr of reperfusion in an anesthetized canine. The superoxide dismutase-mimetic studied (SC- 52608) was a synthetic Mn-based macrocyclic compound. SC-52608 or the inactive analog SC-54385 was administered as four doses of 4 mg/kg i.v. Drug, inactive analog or vehicle was administered 30 and 15 min before ischemia and 15 min and immediately before reperfusion. To ensure parity of left circumflex coronary artery occlusion-induced ischemia, only animals with ischemic zone blood flow of less than 0.15 ml/min/g were included in the final analysis. Ischemic zone blood flow was 0.069 +/- 0.016 ml/min/g in control animals (n = 10), 0.072 +/- 0.010 ml/min/g in SC-52608-treated animals (n = 11) and 0.053 +/- 0.011 ml/min/g in SC-54385-treated (n = 9) animals. A transient hypotensive effect was observed upon SC-52608 administration. Hemodynamic parameters were otherwise unaffected by SC-52608 or SC-54385. The areas at risk of infarct were 39.6 +/- 1.9%, 38.7 +/- 1.1% and 39.4 +/- 1.1% in control, SC-52608-treated and SC-54385-treated animals, respectively. Myocardial infarct sizes (% of area at risk of infarct) were 44.2 +/- 5.6%, 25.7 +/- 4.3% and 35.1 +/- 4.9% in control, SC- 52608-treated and SC-54385-treated animals, respectively (P < .05 control vs. SC-52608-treated). Therefore, the synthetic superoxide dismutase mimetic protected the regionally ischemic and reperfused myocardium from injury, implicating oxygen-derived radicals in the tissue-injury process.
This article has been cited by other articles:
|
|
 |
|
  S. Cuzzocrea, D. P. Riley, A. P. Caputi, and D. Salvemini Antioxidant Therapy: A New Pharmacological Approach in Shock, Inflammation, and Ischemia/Reperfusion Injury Pharmacol. Rev., March 1, 2001; 53(1): 135 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Tanhehco, K. Yasojima, P. L. McGeer, R. A. Washington, and B. R. Lucchesi Free radicals upregulate complement expression in rabbit isolated heart Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H195 - H201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Shankar, K. Hideg, J. L. Zweier, and P. Kuppusamy Targeted Antioxidant Properties of N-[(Tetramethyl-3-pyrroline-3-carboxamido)propyl]phthalimide and Its Nitroxide Metabolite in Preventing Postischemic Myocardial Injury J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 838 - 845. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
